APA (7th ed.) Citation

Kang, Y., Ryu, M., Hong, Y. S., Choi, C., Kim, T. W., Ryoo, B., . . . Sharma, S. (2024). Phase 1/2a Study of Rivoceranib, a Selective VEGFR-2 Angiogenesis Inhibitor, in Patients with Advanced Solid Tumors. Cancer research and treatment, 56(3), 743-750. https://doi.org/10.4143/crt.2023.980

Chicago Style (17th ed.) Citation

Kang, Yoon-Koo, et al. "Phase 1/2a Study of Rivoceranib, a Selective VEGFR-2 Angiogenesis Inhibitor, in Patients with Advanced Solid Tumors." Cancer Research and Treatment 56, no. 3 (2024): 743-750. https://doi.org/10.4143/crt.2023.980.

MLA (9th ed.) Citation

Kang, Yoon-Koo, et al. "Phase 1/2a Study of Rivoceranib, a Selective VEGFR-2 Angiogenesis Inhibitor, in Patients with Advanced Solid Tumors." Cancer Research and Treatment, vol. 56, no. 3, 2024, pp. 743-750, https://doi.org/10.4143/crt.2023.980.